120791-60-8

Basic information

• Product Name: 6-AMino-1,3,3-triMethyl-2-oxoindoline
• Synonyms: 6-AMino-1,3,3-triMethyl-2-oxoindoline;6-AMino-1,3,3-triMethyl-2...;6-amino-1,3,3-trimethyl-2,3-dihydro-1H-indol-2-one;6-Amino-1,3,3-trimethylindolin-2-one
• CAS NO: 120791-60-8
• Molecular Formula: C11H14N2O
• Molecular Weight: 190
• Mol File: 120791-60-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 420.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.140±0.06 g/cm3(Predicted)
• PKA: 3.65±0.40(Predicted)
• CAS DataBase Reference: 6-AMino-1,3,3-triMethyl-2-oxoindoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMino-1,3,3-triMethyl-2-oxoindoline(120791-60-8)
• EPA Substance Registry System: 6-AMino-1,3,3-triMethyl-2-oxoindoline(120791-60-8)

Safety Data

• Hazardous Substances Data: 120791-60-8(Hazardous Substances Data)

Usage

General Description

6-Amino-1,3,3-trimethyl-2-oxoindoline, also known as 6-aminotrimethylindolone, is a chemical compound with the molecular formula C11H14N2O. It is a derivative of indoline and contains an amino group, a ketone group, and three methyl groups. 6-AMino-1,3,3-triMethyl-2-oxoindoline has applications in organic synthesis and can be used as a building block in the production of various pharmaceuticals and agrochemicals. It is also used as a reagent in chemical reactions and as a precursor in the synthesis of other organic compounds. Additionally, this chemical has potential biological activities and is being studied for its potential pharmacological properties.

Upstream product

• 100510-64-3 1,3-Dihydro-3,3-dimethyl-6-nitro-2H-indol-2-one 
• 120791-59-5 1,3-Dihydro-6-nitro-1,3,3-trimethyl-2H-indol-2-one 

Relevant articles and documents

Nonsteroidal Cardiotonics. 2. The Inotropic Activity of Linear, Tricyclic 5-6-5 Fused Heterocycles

We previously reported the structure-activity relationships (SAR) of adibendan (1), a potent and long-acting cardiotonic.This paper describes the synthesis of a novel series of linear, tricyclic fused heterocycles of the 5-6-5 type.The compounds were evaluated for positive inotropic activity in anesthetized rats, cats, and dogs.Changes in left ventricular dP/dt were measured as an index of cardiac contractility.The increase in contractility was not mediated via stimulation of β-adrenergic receptors.The data revealed the intrinsic positive inotropic activity of the parent compound of this series, 5,7-dihydro-7,7-dimethylpyrrolobenzimidazol-6(1H)-one (2).The structural features that impart optimal inotropic activity are presented and compared with those of the 4,5-dihydro-3(2H)-pyridazinone series.The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers to measure ventricular pressures, and their effect on left ventricular dP/dt was compared with that of 1, pimobendan, and indolidan.After administration of 1 mg/kg, 1, 3, 7, 19, 22, 24, 31, 54, pimobendan, and indolidan were equipotent, but only with 1, 31, pimobendan, and indolidan, durations of action exceeded 6 h.